HK inno.N
As of the edition of 20 October 2026, HK inno.N runs 14 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Active | 3 |
| Went quiet | 11 |
| Total | 14 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| NFE2L2 Nuclear factor erythroid 2-related factor 2 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where HK inno.N needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Digestive system: 7 trials led
- Heart and blood vessels: 1 trials led
- Immune system: 1 trials led